Pregabalin CAS 148553-50-8 Maʻemaʻe >99.0% (HPLC) API Antiepileptic

ʻO Pregabalin kahi lāʻau antiepileptic lua o ka hanauna (AED) i ʻike ʻia me ka inoa inoa inoa o Lyrica (Pfizer, Tadworth) ma UK a me USA, loaʻa ka γ-amino butyric acid structure ma kona ʻano mole, nona nā hopena anticonvulsant, a ʻo ia hoʻi. Ua hoʻomohala maikaʻi ʻia e ka hui Pfizer no ka mālama ʻana i ka ʻeha neuropathic peripheral, a i ʻole ka mālama ʻana i nā ʻāpana ʻāpana.ʻO Pregabalin kahi lāʻau Anticonvulsant a me antiepileptic i hoʻohana ʻia e mālama i ka epilepsy, ʻeha neuropathic, fibromyalgia, a me ka maʻi hopohopo ākea.ʻO kona hoʻohana ʻana no ka epilepsy ma ke ʻano he add-on therapy no ka hoʻopaʻa ʻana i ka ʻāpana me ka ʻole o ka generalization lua i nā pākeke.I Dekemaba 2008, ua ʻae ka US Food and Drug Administration (FDA) i ka pregabalin (inoa kālepa "Lyrica") no ka mālama ʻana i ka ʻeha neuropathic peripheral (DPN) a me ka neuralgia postherpetic (PHN) ʻo ia nā ʻeha neuropathic maʻamau.Loaʻa i ka Pregabalin kahi hōʻailona i ʻae ʻia a hoʻohana nui ʻia no ka mālama ʻana i ka maʻi hopohopo ākea.Ua ʻike ʻia kekahi mau hoʻāʻo i hoʻopaʻa ʻia, ʻelua makapō, placebocontrolled he lāʻau maikaʻi ʻo pregabalin no nā poʻe maʻi me ka maʻi hopohopo ākea a me ka pilikia pilikanaka.ʻO ka titration epilepsy-adjunctive therapy: 25 mg bd no 7 mau lā, e hoʻonui ʻia e 50 mg i kēlā me kēia 7 lā;mālama maʻamau 300 mg i kēlā me kēia lā, hoʻokaʻawale ʻia i 2 a i ʻole 3 doses (max. 600 mg i kēlā me kēia lā, i māhele ʻia i 2 a i ʻole 3 doses).ʻO ka maʻi hopohopo nui: 150 mg i kēlā me kēia lā, hoʻokaʻawale ʻia i 2 a i ʻole 3 doses, no 7 mau lā, e hoʻonui ʻia e 150 mg i kēlā me kēia 7 mau lā (max. 600 mg i kēlā me kēia lā, i māhele ʻia i 2 a i ʻole 3 doses).Inā ho'ōki i ka pregabalin, ua ʻōlelo ʻia e hoʻopaʻa i ka liʻiliʻi ma kahi o 1 pule e pale ai i ka haʻalele koke ʻana.'Ōlelo Aʻo No nā maʻi me nā kūlana e hiki ke hoʻomaka i ka encephalopathy.ʻO nā maʻi me ka puʻuwai congestive koʻikoʻi.